Insights
Search Results
Client Highlights
6.01.26
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to $32.5 Million Series A Financing
On June 1, 2026, Oak Hill Bio, a clinical-stage rare disease therapeutics company, announced the closing of a $32.5 million Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises Frazier Life Sciences on IP Matters Related to Immutrin’s $87 Million Series A
On March 24, 2026, Immutrin, a biotechnology company developing next generation antibody therapy to reverse amyloidosis, announced it has successfully raised $87 million in a Series A financing. The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.
Client Highlights
10.28.25
Wilson Sonsini Advises Empirico on License Agreement with GSK
On October 28, 2025, GSK and Empirico, a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide. EMP-012 addresses a novel therapeutic target and is currently in a Phase 1 trial for the treatment of chronic obstructive pulmonary disease (COPD), with the potential for expansion into other inflammatory respiratory diseases. Wilson Sonsini Goodrich & Rosati advised Empirico on the transaction.
Client Highlights
10.01.25
Firm Advises Predicta Biosciences on IP Matters Related to Oversubscribed $23.4 Million Series A
On October 1, 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4 million Series A financing led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute, and Myeloma Solutions Fund. Wilson Sonsini Goodrich & Rosati advised Predicta on IP matters related to the transaction.
Client Highlights
9.05.25
Firm Advises Enlaza on IP Matters Related to Multi-Target Drug Discovery Collaboration with Vertex Pharmaceuticals
On September 2, 2025, Enlaza Therapeutics, the first covalent biologics platform company, announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction.
Client Highlights
4.15.25
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to Exclusive License Agreement with Roche
On April 15, 2025, Oak Hill Bio, a biotechnology company focused on acquiring and developing life-changing rare disease therapeutics, entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). Rugonersen is an ASO designed as a potential best-in-class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
Client Highlights
12.20.24
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio
On December 19, 2024, Aadi Bioscience announced that it had entered into an agreement to sell its commercial drug product FYARRO® to KAKEN Pharmaceutical for $100 million, an agreement to sell and issue $100 million of equity in a PIPE financing, and an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics, a global Contract Research, Development and Manufacturing Organization, and Hangzhou DAC, a global leader in ADC innovation.
Client Highlights
5.01.24
Wilson Sonsini Advises Enlaza Therapeutics on IP Matters Related to $100 Million Series A
On April 30, 2024, Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it successfully closed a $100 million Series A financing. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the Series A and represents the company in patent strategy and prosecution matters.
Client Highlights
5.03.22
Firm Advises Belite Bio on IP Matters Related to $36 Million IPO
On April 28, 2022, Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of its initial public offering of six million American Depositary Shares (ADSs) at a public offering price per ADS of $6.00. Each ADS represents one ordinary share of Belite. In addition, Belite has granted the underwriters a 30-day option to purchase an additional 900,000 ADSs at the initial public offering price, less underwriting discounts and commissions. Lin Bioscience International Ltd., the company’s principal shareholder, agreed to purchase $15.0 million of ADSs in the offering. Wilson Sonsini Goodrich & Rosati advised Belite Bio on intellectual property matters related to the transaction.
In connection with the offering, Belite’s ADSs have been approved for listing on the Nasdaq Capital Market. The ADSs began trading on April 29, 2022, under the ticker symbol “BLTE.” The offering closed on May 3, 2022. The gross proceeds to Belite from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $36 million. Belite expects to use the net proceeds to fund the Phase 3 clinical trial of its lead candidate, LBS-008, for Stargardt disease (an inherited juvenile form of macular degeneration) and for further clinical development of LBS-008 for dry age-related macular degeneration (AMD), working capital, and other general corporate purposes.
Founded in 2016, San Diego, California-based Belite Bio targets untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Wilson Sonsini has handled all IP matters for Belite since the company’s inception.
The Wilson Sonsini team advising Belite on intellectual property matters related to the IPO was led by Deborah Smith, Sean Reed, and Matt Bresnahan.
For more information, please see Belite’s press release.
In connection with the offering, Belite’s ADSs have been approved for listing on the Nasdaq Capital Market. The ADSs began trading on April 29, 2022, under the ticker symbol “BLTE.” The offering closed on May 3, 2022. The gross proceeds to Belite from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $36 million. Belite expects to use the net proceeds to fund the Phase 3 clinical trial of its lead candidate, LBS-008, for Stargardt disease (an inherited juvenile form of macular degeneration) and for further clinical development of LBS-008 for dry age-related macular degeneration (AMD), working capital, and other general corporate purposes.
Founded in 2016, San Diego, California-based Belite Bio targets untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Wilson Sonsini has handled all IP matters for Belite since the company’s inception.
The Wilson Sonsini team advising Belite on intellectual property matters related to the IPO was led by Deborah Smith, Sean Reed, and Matt Bresnahan.
For more information, please see Belite’s press release.
Client Highlights
7.29.20
Wilson Sonsini Advises MBX Biosciences in $35 Million Series A Financing
On July 27, 2020, MBX Biosciences, a drug discovery company focused in rare endocrine diseases, announced the closing of a $34.6 million Series A financing. The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads), and Twilight Venture Partners II. Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets. The company is built upon the medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, Ph.D., co-founder and chief scientific officer of MBX. The company seeks to address rare endocrine disorders with substantial unmet medical need.
Client Highlights
12.11.19
Wilson Sonsini Advises Synthorx on Patent Matters Related to $2.5 Billion Acquisition by Sanofi
On December 9, 2019, Sanofi and Synthorx announced that the companies have entered into an agreement under which Sanofi will acquire Synthorx, a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion. The transaction was unanimously approved by both the Sanofi and Synthorx boards of directors. Wilson Sonsini has acted as patent counsel for Synthorx from its inception, including patent strategy, counseling, and prosecution. The Wilson Sonsini patent team was responsible for the patent diligence underlying this transaction.